HIM
AMRX icon

Hillsdale Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Hillsdale Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Sell
649,179
-94,500
-13% -$1.29M 0.26% 90
2026
Q1 		$9.24M Buy
743,679
+29,150
+4% +$391K 0.25% 68
2025
Q4 		$9M Sell
714,529
-1,500
-0.2% -$17.2K 0.25% 70
2025
Q3 		$7.17M Buy
716,029
+715,229
+89,404% +$6.42M 0.22% 117
2025
Q2 		$6.47K Buy
800
+50
+7% +$377 ﹤0.01% 570
2025
Q1 		$6.29K Buy
+750
New +$6.26K ﹤0.01% 540
2024
Q2 		– Sell
-699,719
Closed -$4.24M – 580
2024
Q1 		$4.24M Buy
699,719
+115,100
+20% +$649K 0.34% 108
2023
Q4 		$3.55M Buy
584,619
+541,000
+1,240% +$2.41M 0.29% 135
2023
Q3 		$184K Buy
+43,619
New +$163K 0.02% 352
2022
Q4 		– Sell
-861,716
Closed -$1.74M – 550
2022
Q3 		$1.74M Hold
861,716
– – 0.16% 155
2022
Q2 		$2.74M Hold
861,716
– – 0.22% 147
2022
Q1 		$3.59M Sell
861,716
-8,200
-0.9% -$36.3K 0.23% 148
2021
Q4 		$4.17M Sell
869,916
-2,600
-0.3% -$13K 0.28% 125
2021
Q3 		$4.66M Buy
872,516
+85,700
+11% +$431K 0.36% 87
2021
Q2 		$4.03M Buy
786,816
+175,616
+29% +$998K 0.32% 110
2021
Q1 		$4.11M Buy
+611,200
New +$3.39M 0.34% 97

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Hillsdale Investment Management's AMRX Position: Q2 2026 in Review

Hillsdale Investment Management reduced its Amneal Pharmaceuticals (AMRX) stake by 13% in Q2 2026, selling an estimated $1.29M and leaving 649,179 shares worth $11.2M. The position accounts for 0.26% of the portfolio, ranked #90.

Hillsdale Investment Management first reported a position in AMRX in Q1 2021 and has held it in 16 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Hillsdale Investment Management held 649,179 shares of Amneal Pharmaceuticals worth $11.2M as of Q2 2026.
  • Hillsdale Investment Management sold 94,500 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.29M.
  • Amneal Pharmaceuticals made up 0.26% of Hillsdale Investment Management's portfolio in Q2 2026, its #90 holding.
  • Hillsdale Investment Management first reported a position in Amneal Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.